{"id":60970,"date":"2024-02-28T07:18:18","date_gmt":"2024-02-28T07:18:18","guid":{"rendered":"https:\/\/medsname.com\/selgin\/"},"modified":"2026-05-01T10:49:16","modified_gmt":"2026-05-01T10:49:16","slug":"selgin","status":"publish","type":"product","link":"https:\/\/medsbase.com\/el\/selgin\/","title":{"rendered":"Selgin"},"content":{"rendered":"

<\/p>\n

\n

⚡ Quick Answer<\/h3>\n

Selgin<\/strong> \u03b5\u03af\u03bd\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03bf\u03c5 \u03c3\u03c4\u03cc\u03bc\u03b1\u03c4\u03bf\u03c2 selegiline<\/strong> (5 mg) tablet \u2014 a selective monoamine oxidase type B (MAO-B) inhibitor<\/strong> \u03c7\u03c1\u03b7\u03c3\u03b9\u03bc\u03bf\u03c0\u03bf\u03b9\u03b5\u03af\u03c4\u03b1\u03b9 \u03b3\u03b9\u03b1 \u03c4\u03b7 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1 Parkinson disease<\/strong>. By blocking MAO-B in the brain, it slows the breakdown of dopamine and helps lengthen the time levodopa keeps working between doses (reduces “off” time). Selegiline is metabolised to L-amphetamine and L-methamphetamine<\/strong>, which can contribute to insomnia — take morning doses only. Common side effects: insomnia, headache, dyskinesia, dry mouth, postural hypotension. \u03a3\u03b7\u03bc\u03b1\u03bd\u03c4\u03b9\u03ba\u03cc:<\/strong> avoid combination with most antidepressants (SSRIs, SNRIs, TCAs), opioids such as pethidine and tramadol, and dextromethorphan — risk of \u03c3\u03cd\u03bd\u03b4\u03c1\u03bf\u03bc\u03bf \u03c3\u03b5\u03c1\u03bf\u03c4\u03bf\u03bd\u03af\u03bd\u03b7\u03c2<\/em>.<\/p>\n<\/div>\n

\n\u0391\u03c5\u03c4\u03cc \u03c0\u03bf\u03c5 \u03bb\u03b1\u03bc\u03b2\u03ac\u03bd\u03b5\u03c4\u03b5 \u03bc\u03b5 \u03c4\u03b7\u03bd MedsBase:<\/strong> \u03a0\u03b9\u03c3\u03c4\u03bf\u03c0\u03bf\u03b9\u03b7\u03bc\u03ad\u03bd\u03bf\u03c2 \u03ba\u03b1\u03c4\u03b1\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03c4\u03ae\u03c2 WHO-GMP \u00b7 \u0394\u03b9\u03b1\u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ae \u03c3\u03c5\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03af\u03b1 \u00b7 \u03a0\u03b1\u03b3\u03ba\u03cc\u03c3\u03bc\u03b9\u03b1 \u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae \u00b7 1,400+ \u03b5\u03c0\u03b1\u03bb\u03b7\u03b8\u03b5\u03c5\u03bc\u03ad\u03bd\u03b5\u03c2 \u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ad\u03c2 \u03c0\u03b5\u03bb\u03b1\u03c4\u03ce\u03bd<\/a>\n<\/div>\n

\ud83d\udce6 \u039a\u03ac\u03b8\u03b5 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03bb\u03af\u03b1 \u03ba\u03b1\u03bb\u03cd\u03c0\u03c4\u03b5\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03a0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae \u0395\u03b3\u03b3\u03cd\u03b7\u03c3\u03b7\u03c2 \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2<\/strong><\/a> \u2014 \u03b5\u03ac\u03bd \u03c4\u03bf \u03b4\u03ad\u03bc\u03b1 \u03c3\u03b1\u03c2 \u03b4\u03b5\u03bd \u03c6\u03c4\u03ac\u03c3\u03b5\u03b9 \u03b5\u03bd\u03c4\u03cc\u03c2 20 \u03b5\u03c1\u03b3\u03ac\u03c3\u03b9\u03bc\u03c9\u03bd \u03b7\u03bc\u03b5\u03c1\u03ce\u03bd, \u03c4\u03bf \u03b5\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03ad\u03bb\u03bb\u03bf\u03c5\u03bc\u03b5.<\/p>\n

\u0393\u03b9\u03b1\u03c4\u03af \u03bd\u03b1 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03af\u03bb\u03b5\u03c4\u03b5 \u03b1\u03c0\u03cc \u03c4\u03b7 MedsBase<\/h3>\n

\u03a4\u03b1 \u03b3\u03b5\u03bd\u03cc\u03c3\u03b7\u03bc\u03b1 \u03c6\u03ac\u03c1\u03bc\u03b1\u03ba\u03ac \u03bc\u03b1\u03c2 \u03c0\u03c1\u03bf\u03ad\u03c1\u03c7\u03bf\u03bd\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03ba\u03b1\u03c4\u03b1\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03c4\u03ad\u03c2 \u03c0\u03bf\u03c5 \u03c0\u03b9\u03c3\u03c4\u03bf\u03c0\u03bf\u03b9\u03bf\u03cd\u03bd\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd WHO-GMP \u03ba\u03b1\u03b9 \u03b1\u03c0\u03bf\u03c3\u03c4\u03ad\u03bb\u03bb\u03bf\u03bd\u03c4\u03b1\u03b9 \u03c0\u03b1\u03b3\u03ba\u03bf\u03c3\u03bc\u03af\u03c9\u03c2 \u03c3\u03b5 \u03b4\u03b9\u03b1\u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ae, \u03b1\u03c0\u03bb\u03ae \u03c3\u03c5\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03af\u03b1 \u2014 \u03c7\u03c9\u03c1\u03af\u03c2 \u03cc\u03bd\u03bf\u03bc\u03b1 \u03c6\u03b1\u03c1\u03bc\u03ac\u03ba\u03bf\u03c5 \u03c3\u03c4\u03bf \u03b5\u03be\u03c9\u03c4\u03b5\u03c1\u03b9\u03ba\u03cc \u03c4\u03bf\u03c5 \u03b4\u03ad\u03bc\u03b1\u03c4\u03bf\u03c2. \u039f\u03b9 \u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03ad\u03c2 \u03bc\u03b5 \u03ba\u03ac\u03c1\u03c4\u03b1 \u03b4\u03c1\u03bf\u03bc\u03bf\u03bb\u03bf\u03b3\u03bf\u03cd\u03bd\u03c4\u03b1\u03b9 \u03bc\u03ad\u03c3\u03c9 \u03c1\u03c5\u03b8\u03bc\u03b9\u03c3\u03bc\u03ad\u03bd\u03bf\u03c5 \u03b5\u03c0\u03b5\u03be\u03b5\u03c1\u03b3\u03b1\u03c3\u03c4\u03ae (\u03bf\u03b9 \u03c0\u03b5\u03c1\u03b9\u03b3\u03c1\u03b1\u03c6\u03ad\u03c2 \u03b5\u03ba\u03ba\u03b1\u03b8\u03ac\u03c1\u03b9\u03c3\u03b7\u03c2 \u03c0\u03b5\u03c1\u03b9\u03bb\u03b1\u03bc\u03b2\u03ac\u03bd\u03bf\u03c5\u03bd \u03c1\u03c5\u03b8\u03bc\u03b9\u03c3\u03bc\u03ad\u03bd\u03bf \u03b5\u03c0\u03b5\u03be\u03b5\u03c1\u03b3\u03b1\u03c3\u03c4\u03ae \u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03ce\u03bd \u03bc\u03b5 \u03ba\u03ac\u03c1\u03c4\u03b1 \u2014 \u03c0\u03bf\u03c4\u03ad \u201cMedsBase\u201d \u03ae \u03bf\u03c0\u03bf\u03b9\u03bf\u03b4\u03ae\u03c0\u03bf\u03c4\u03b5 \u03cc\u03bd\u03bf\u03bc\u03b1 \u03c6\u03b1\u03c1\u03bc\u03ac\u03ba\u03bf\u03c5). \u0393\u03af\u03bd\u03bf\u03bd\u03c4\u03b1\u03b9 \u03b4\u03b5\u03ba\u03c4\u03ad\u03c2 \u03ba\u03b1\u03b9 \u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03ad\u03c2 \u03bc\u03b5 \u03ba\u03c1\u03c5\u03c0\u03c4\u03bf\u03bd\u03bf\u03bc\u03af\u03c3\u03bc\u03b1\u03c4\u03b1 \u03ba\u03b1\u03b9 \u03c4\u03c1\u03b1\u03c0\u03b5\u03b6\u03b9\u03ba\u03ae \u03bc\u03b5\u03c4\u03b1\u03c6\u03bf\u03c1\u03ac SEPA. \u039a\u03ac\u03b8\u03b5 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03bb\u03af\u03b1 \u03ba\u03b1\u03bb\u03cd\u03c0\u03c4\u03b5\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03a0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2 \u0395\u03be\u03b1\u03c3\u03c6\u03b1\u03bb\u03af\u03c3\u03b5\u03ce\u03c2 \u03bc\u03b1\u03c2.<\/p>\n

What Is Selgin?<\/h2>\n

Selgin is an oral tablet containing selegiline 5 mg<\/strong>. selegiline is a selective monoamine oxidase type B (MAO-B) inhibitor<\/strong> originally introduced as Eldepryl \/ Jumex<\/strong>. Selgin is manufactured by a WHO-GMP certified facility and is bioequivalent to the originator brand at the same strength.<\/p>\n

Selegiline was the first MAO-B inhibitor used in Parkinson disease, in clinical use since the 1980s. It can be used as monotherapy<\/em> in early Parkinson disease (modest symptomatic benefit, may delay the need for levodopa by months) or as adjunct<\/em> to levodopa to reduce “wearing-off” between doses. Its distinctive feature among MAO-B inhibitors is that it is metabolised to amphetamine derivatives, which contribute to a mild stimulant effect — useful for fatigue but a frequent cause of insomnia.<\/p>\n

How Does Selgin (selegiline) Work?<\/h2>\n

In the brain, dopamine is degraded mainly by monoamine oxidase type B (MAO-B). Selegiline irreversibly inactivates MAO-B at standard doses (5–10 mg\/day), so dopamine released from surviving neurones lingers longer in the synapse. The result: smoother symptom control and a longer benefit from each levodopa dose. Selegiline is also metabolised to L-amphetamine and L-methamphetamine, which independently contribute mild stimulant and dopaminergic effects. Above 10 mg\/day, selectivity for MAO-B is lost and MAO-A inhibition becomes clinically meaningful — tyramine restriction then becomes important.<\/p>\n

Comparing the MAO-B Inhibitors<\/h2>\n

The three MAO-B inhibitors used in Parkinson disease — selegiline, rasagiline and safinamide — share a common mechanism but differ meaningfully in metabolites, dosing and clinical positioning:<\/p>\n\n\n\n\n\n\n\n\n\n
\u03a7\u03b1\u03c1\u03b1\u03ba\u03c4\u03b7\u03c1\u03b9\u03c3\u03c4\u03b9\u03ba\u03cc<\/th>\nSelegiline<\/th>\nRasagiline<\/th>\nSafinamide<\/th>\n<\/tr>\n<\/thead>\n
Typical dose<\/td>\n5–10 mg\/day<\/td>\n0.5–1 mg\/day<\/td>\n50–100 mg\/day<\/td>\n<\/tr>\n
Active metabolites<\/td>\nAmphetamine + methamphetamine<\/td>\nAminoindan (non-amphetamine)<\/td>\nNo active stimulant metabolite<\/td>\n<\/tr>\n
Glutamate effect<\/td>\n\u038c\u03c7\u03b9<\/td>\n\u038c\u03c7\u03b9<\/td>\nYes<\/strong> — sodium-channel\/glutamate-release modulation<\/td>\n<\/tr>\n
\u0395\u03bd\u03b4\u03b5\u03af\u03be\u03b5\u03b9\u03c2<\/td>\nMonotherapy or adjunct<\/td>\nMonotherapy or adjunct<\/td>\nAdjunct only<\/strong> — for fluctuating PD on levodopa<\/td>\n<\/tr>\n
Insomnia risk<\/td>\nHigher (amphetamine metabolites)<\/td>\nLow<\/td>\nLow<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Who Is Selgin For?<\/h2>\n

Selgin is appropriate for adults with Parkinson disease — either as initial monotherapy in early disease (when symptoms are mild and the patient is reluctant to start levodopa) or as adjunct to levodopa in patients with end-of-dose “wearing-off”. Older patients prone to insomnia may tolerate rasagiline or safinamide better. Not appropriate during current SSRI\/SNRI\/TCA therapy or for patients planning to take pethidine, tramadol or other contraindicated medications.<\/p>\n

Dosing and Administration<\/h2>\n

The standard adult dose is 5 mg once daily with breakfast<\/strong>, increased to 5 mg twice daily (breakfast and lunch) after 1–2 weeks<\/strong> if needed for symptom control. Avoid evening doses<\/em> — the amphetamine metabolites cause insomnia. Maximum 10 mg\/day at standard MAO-B selectivity. Doses up to 20–30 mg\/day have been used historically but cross into non-selective MAO inhibition with full tyramine-diet implications.<\/p>\n\n\n\n\n\n\n\n
\u03a6\u03ac\u03c3\u03b7<\/th>\n\u0394\u03cc\u03c3\u03b7<\/th>\nTiming<\/th>\n<\/tr>\n<\/thead>\n
Week 1–2 (initiation)<\/td>\n5 mg once daily<\/td>\nWith breakfast<\/td>\n<\/tr>\n
\u03a3\u03c5\u03bd\u03c4\u03ae\u03c1\u03b7\u03c3\u03b7<\/td>\n5 mg twice daily<\/td>\nBreakfast and lunch — never evening<\/td>\n<\/tr>\n
Maximum at MAO-B selectivity<\/td>\n10 mg\/day<\/td>\nBeyond this, tyramine restriction needed<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
⚠ Tyramine and the “cheese effect”<\/strong> At standard MAO-B-selective doses, dietary tyramine restriction is generally \u03b4\u03b5\u03bd<\/em> required. However, MAO-B selectivity is dose-dependent — selegiline above 10 mg\/day, rasagiline above 1 mg\/day, and safinamide above 100 mg\/day lose selectivity and inhibit peripheral MAO-A as well. At those doses, tyramine-rich foods (aged cheeses, cured meats, broad beans, fermented soya, draught beer) can trigger a hypertensive crisis. Stay within prescribed doses to avoid this risk.<\/div>\n

\u03a3\u03c5\u03c7\u03bd\u03ad\u03c2 \u03c0\u03b1\u03c1\u03b5\u03bd\u03ad\u03c1\u03b3\u03b5\u03b9\u03b5\u03c2<\/h2>\n

Insomnia (very common — the most common reason for discontinuation), headache, nausea, dizziness, postural hypotension, dry mouth, increased liver enzymes. Less common: confusion, hallucinations, agitation, mood changes. With levodopa: increased dyskinesia, may need to lower the levodopa dose by 10–30%.<\/p>\n

⚠ Serotonin syndrome — dangerous interactions<\/strong> Combining a MAO-B inhibitor with serotonergic drugs can cause \u03c3\u03cd\u03bd\u03b4\u03c1\u03bf\u03bc\u03bf \u03c3\u03b5\u03c1\u03bf\u03c4\u03bf\u03bd\u03af\u03bd\u03b7\u03c2<\/em>: agitation, sweating, tremor, hyperreflexia, fever, diarrhoea, in severe cases seizures and death. Avoid:<\/strong> SSRIs (fluoxetine, sertraline, paroxetine, citalopram, escitalopram), SNRIs (venlafaxine, duloxetine), tricyclics (amitriptyline, imipramine), pethidine (meperidine), tramadol, dextromethorphan, methadone, St John’s wort, MDMA. Wash-out periods:<\/strong> stop fluoxetine 5 weeks before starting MAO-B inhibitor; stop other SSRIs\/SNRIs at least 2 weeks before; do not start fluoxetine within 2 weeks of stopping the MAO-B inhibitor.<\/div>\n

Drug and Food Interactions<\/h2>\n